No abstract

No abstract

No abstract

Release of leachable products from resinous compounds in the saliva of children with anterior open bite treated with spurTo evaluate the release of bisphenol-A glycidyl methacrylate (BisGMA), triethylene glycol dimethacrylate (TEGDMA), bisphenol A (BPA), and phthalates of the composite resin used in the bonding of spurs applied in the treatment of children with anterior open bite and its effects on human keratinocytes. Methodology: Saliva samples of 22 children were collected before spur attachment (baseline) and 30 minutes (min) and 24 hours (h) after spur bonding. Analysis was performed using high-performance liquid chromatography (HPLC) coupled to tandem mass spectrometry (HPLC-MS/ MS) and gas chromatography coupled to mass spectrometry (GC-MS).Standardized resin increments were added to three different dilutions of the cell culture medium. Keratinocytes (HaCaT) were cultivated in the conditioned media and evaluated for cell viability (MTT) and cell scratch assay. Results:The levels of BisGMA (1.74±0.27 μg/mL), TEGDMA (2.29±0.36 μg/mL), and BPA (3.264±0.88 μg/L) in the saliva after 30 min, in comparison to baseline (0±0 μg/mL, 0±0 μg/mL, and 1.15±0.21 μg/L, respectively), presented higher numbers. After 24 h, the levels of the monomers were similar to the baseline. Phthalates showed no significant difference among groups. HaCat cells showed increased viability and reduced cell migration over time after exposure to methacrylate-based resin composites. Conclusion: Resin composites, used to attach spurs in children with anterior open bite during orthodontic treatment, release monomers after polymerization and can influence the behavior of human keratinocytes, even at very low concentrations. Orthodontists should be aware of the risks of the resinous compounds release and preventive procedures should be held to reduce patient exposure.

Aim To evaluate the impact of this program in risk factors control and events. Methods 514 consecutive MI patients hospitalised in six public hospitals. Data collection was obtained by a review of medical records and a 12-month interview (anthropometric and biochemical measurements, lifestyle information and pharmacological treatment). Predictors of good control were evaluated with multilevel analysis. Results follow-up was available in 398 patients (77.4%), 75% were male, aged 62.1 years (SD 611.7). At the time of interview 8.6% were smokers; 24% reported regular physical activity; 78.6% were overweight or obese. The proportion of patients with raised systolic blood pressure was 46.3% and raised diastolic blood pressure was found in 35.4%. 28.9% had LDL cholesterol $100 mg/dl and 21.1% glucose $100 mg/dl. In diabetic patients (24.1%), 52% had glycosilated haemoglobin $7.0%. The use of drug therapies at month 12 was: aspirin 95.5%, b-blockers 70.6%, ACE inhibitors 64.0% and